Rx Product News

Pharmacy TimesApril 2013 Allergy & Asthma
Volume 79
Issue 4


Marketed by: Ranbaxy Laboratories Inc

Indication: Ranbaxy Laboratories Inc has launched Absorica capsules (isotretinoin), which are indicated for the treatment of severe recalcitrant nodular acne in patients 12 years and older. The recommended dosage is 0.5 to 1 mg/ kg/day given in 2 divided doses without regard for meals. Absorica must not be used by female patients who are or may become pregnant while taking the drug, due to an extremely high risk of severe birth defects.

Dosage Form: Capsules: 10, 20, 30, and 40 mg

For More Information: www.ranbaxyusa.com

Prevnar 13

Marketed by: Pfizer Inc

Indication: The FDA has approved an expanded use of Prevnar 13 (Pneumococcal 13-valent Conjugate Vaccine [Diphtheria CRM197 Protein]) in older children and adolescents aged 6 through 17 years for active immunization for the prevention of invasive disease caused by the 13 Streptococcus pneumoniae serotypes contained in the vaccine. For this age group it is given as a single dose in treatment-naive patients.

Dosage Form: Intramuscular injection: 0.5-mL suspension supplied in a single-dose prefilled syringe

For More Information: www.prevnar.com


Marketed by: Novartis Pharmaceuticals

Indication: Expanded use of Gleevec (imatinib mesylate) tablets to treat newly diagnosed pediatric patients with Philadelphia chromosome-positive chronic myeloid leukemia (Ph+ CML) in the chronic phase has been approved by the FDA. The dose indicated for pediatric patients is 340 mg/m2/day. Doses of Gleevec should be taken with a meal and a large glass of water. The medication may be dissolved in water or apple juice for patients who are having difficulty swallowing.

Dosage Form: Tablets (scored): 100, 400 mg

For More Information: www.gleevec.com


Marketed by: Bayer HealthCare Pharmaceuticals

Indication: The FDA has expanded the approved use of Stivarga (regorafenib) to treat patients with locally advanced, unresectable, or metastatic gastrointestinal stromal tumor (GIST) who have been previously treated with imatinib mesylate and sunitinib malate. It carries a boxed warning on hepatotoxicity that recommends the monitoring of hepatic function prior to and during treatment. The recommended dose is 160 mg orally with a low-fat breakfast once daily for the first 21 days of each 28-day cycle.

Dosage Form: 40-mg film-coated tablets

For More Information: www.stivarga-us.com

Related Videos
Practice Pearl #1 Active Surveillance vs Treatment in Patients with NETs
© 2024 MJH Life Sciences

All rights reserved.